Log In
Print this Print this

Bydureon (Exenatide once weekly)

Also known as: Byetta LAR, exenatide LAR (AC2993 LAR)

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionLong-acting release (LAR) formulation of synthetic exendin-4
Molecular Target Glucagon-like peptide-1 receptor (GLP-1R) (GLP1R)
Mechanism of ActionGlucagon-like peptide-1 (GLP-1) receptor agonist
Therapeutic ModalityPeptide
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes; Treat Type II diabetes in combination with metformin, a sulfonylurea, a thiazolidinedione, metformin plus a sulfonylurea or metformin plus a thiazolidinedione
Regulatory Designation
Partner3SBio Inc.;
Alkermes plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today